Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Graciela M. Nogueras-González"'
Autor:
Naval Daver, Jayastu Senapati, Abhishek Maiti, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Elias Jabbour, Guillermo Montalban-Bravo, Guilin Tang, Koji Sasaki, Gautam Borthakur, Musa Yilmaz, Joie Alvarez, Sherry A. Pierce, Graciela M. Nogueras González, Jing Ning, Ghayas C. Issa, Michael Andreeff, Hussein A Abbas, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian
Publikováno v:
Blood. 140:141-144
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Autor:
Alexandre Bazinet, Tapan M. Kadia, Nicholas Short, Gautam Borthakur, Sa A Wang, Sanam Loghavi, Jeffrey L. Jorgensen, Keyur P. Patel, Courtney D. DiNardo, Naval Daver, Yesid Alvarado, Fadi Haddad, Sherry A. Pierce, Graciela M. Nogueras González, Abhishek Maiti, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Publikováno v:
Blood. 140:2267-2269
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
The following information describes additional study design criteria and safety considerations used in the phase 1 clinical trial of RG7112 in patients with hematological malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448e7208c04cf15744fde05f7fa0ec5d
https://doi.org/10.1158/1078-0432.22460697.v1
https://doi.org/10.1158/1078-0432.22460697.v1
Autor:
Marina Konopleva, Farhad Ravandi, Michael Andreeff, Hagop M. Kantarjian, Xuelin Huang, Jorge Cortes, John F. DiPersio, Mike Rettig, Stefan O. Ciurea, Gheath AI-Atrash, Jin Zhou, Sa A. Wang, Hong Mu, Rongqing Pan, Antonio Cavazos, Graciela M. Nogueras González, Qi Zhang, Ce Shi, Chris Brooks, Jeffrey L. Jorgensen, Lina Han
Supplemental Table 1. Clinical characteristics of non-APL AML patients with MRD data Supplemental Table 2. Flow cytometry panel for MRD Supplemental Table 3. Proportions of AML blasts, CD34+ cells, and CD123+ cells at diagnosis and in remission in 86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d79580902db0a7d7dcbd0517edc9aa
https://doi.org/10.1158/1078-0432.22462671.v1
https://doi.org/10.1158/1078-0432.22462671.v1
Autor:
Marina Konopleva, Farhad Ravandi, Michael Andreeff, Hagop M. Kantarjian, Xuelin Huang, Jorge Cortes, John F. DiPersio, Mike Rettig, Stefan O. Ciurea, Gheath AI-Atrash, Jin Zhou, Sa A. Wang, Hong Mu, Rongqing Pan, Antonio Cavazos, Graciela M. Nogueras González, Qi Zhang, Ce Shi, Chris Brooks, Jeffrey L. Jorgensen, Lina Han
Purpose: The persistence of leukemia stem cells (LSC)-containing cells after induction therapy may contribute to minimal residual disease (MRD) and relapse in acute myeloid leukemia (AML). We investigated the clinical relevance of CD34+CD123+ LSC-con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31abb22f203d2e14427de5e15e35deac
https://doi.org/10.1158/1078-0432.c.6525171.v1
https://doi.org/10.1158/1078-0432.c.6525171.v1
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
Supplementary Fig. 1. Day 10 dose-mean PK profiles in patients with leukemia; Supplementary Figure 2. RG7112 induces p53-mediated apoptosis in circulating lymphoma cells from a patient with SLL/CLL (810 mg to 1500 mg BID)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ff90eadcc873d56ed29004c7759a71
https://doi.org/10.1158/1078-0432.22460700
https://doi.org/10.1158/1078-0432.22460700
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
Supplementary Table 1. Study stratification and dosing regimen; Supplementary Table 2. p53 target genes examined in this study; Supplementary Table 3. Characteristics of evaluable patients treated at the MTD; Supplementary Table 4. Patient demographi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54f4cc19642954ea5217002d26030405
https://doi.org/10.1158/1078-0432.22460694.v1
https://doi.org/10.1158/1078-0432.22460694.v1
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
Purpose: RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in patients with hematologic malignancies was conducted.Experimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73b8f506539b36aa97ffa998f3a1ed9f
https://doi.org/10.1158/1078-0432.c.6524571.v1
https://doi.org/10.1158/1078-0432.c.6524571.v1
Autor:
Guofan Xu, Lei Feng, Hun Ju Lee, Michelle Avellaneda, Preetesh Jain, Linghua Wang, Luis Fayad, Omar Moghrabi, L. Jeffrey Medeiros, Cezar Iliescu, Nathan Fowler, Shuangtao Zhao, Yang Liu, Selvi Thirumurthi, Michael L. Wang, Chi Young Ok, Maria Badillo, Lucy Navsaria, Graciela M. Nogueras González, David Santos, Christopher R. Flowers, Francisco Vega, Guilin Tang, Holly Hill, Rashmi Kanagal-Shamanna, Fredrick B. Hagemeister, Yixin Yao
Publikováno v:
J Clin Oncol
PURPOSE Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously untreated older patients with MCL (age ≥ 65 y